PER 4.65% 9.0¢ percheron therapeutics limited

Fresh Start, page-10

  1. 720 Posts.
    lightbulb Created with Sketch. 210
    Well put together and thank you Sam. Agree with the thoughts and questions raised.

    I agree that funding is the major concern, and once they start the P2b trial in earnest they’ll have about 9 months max before money runs out.

    Contrary to some in here who believe the first jab is going to lift the share price, imo the first jab will set the funding shortfall ball in motion and put a nearby deadline on a cap raise. This would explain why they dithered on starting the pivotal trial in early 2022, before changing the trial plan, and why they’re dithering now imo (apologies to Board and Mgmt if the funding problem has been solved but not divulged).

    It’s 6 months since they announced the new trial plan and they haven’t even submitted applications in Australia yet.

    Of course, Itsa’s right on one point he makes, we don’t know what is going on behind the scenes, and if they have funding sources earmarked just waiting for (say) completed mouse combo results.

    Likely they have been speaking with some interested third party (my speculation), hence the introduction of the tox study as a priority (post the trial redraft) - an extra $3 mill cost when we’re already short of money.

    I kind of agree with Deano in that it wouldn’t surprise if they announce another pivot to a combo trial, assuming further analysis results are good, though again that is complete speculation.

    Why isn’t Ionis interested in reclaiming ATL1102? They could go to from single figure payaway share to 100% share (albeit with further development cost) for a pittance of the potential $5 bill that’s been bandied about in here as ATL1102’s potential commercial value. The Orphan Drug Designation in Europe and US is a big carrot on a stick.

    The perfect storm for minor shareholders is a NeuroBo situation, where the SP subsides without any funding source to the point where we are diluted considerably in a backs to the wall restructuring/share grab by a large vulture. Let’s hope that scenario doesn’t develop. Not sure it can anyway with ASX rules.



    Last edited by BoomCrashOffera: 16/03/23
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
9.0¢
Change
0.004(4.65%)
Mkt cap ! $81.13M
Open High Low Value Volume
8.6¢ 9.1¢ 8.5¢ $181.6K 2.049M

Buyers (Bids)

No. Vol. Price($)
1 10344 8.7¢
 

Sellers (Offers)

Price($) Vol. No.
9.0¢ 64275 1
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.